A Partially-Blind (Observer-Blind) Study to Evaluate the Safety and Immunogenicity of 3 Different Vaccination Schedules With 2 GSK Biologicals' Candidate Plasmodium Falciparum Vaccines in Children Aged 5 to 17 Months Living in Ghana.

Trial Profile

A Partially-Blind (Observer-Blind) Study to Evaluate the Safety and Immunogenicity of 3 Different Vaccination Schedules With 2 GSK Biologicals' Candidate Plasmodium Falciparum Vaccines in Children Aged 5 to 17 Months Living in Ghana.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Sep 2009

At a glance

  • Drugs GSK 257049 (Primary) ; AS01E; AS02; Rabies vaccine
  • Indications Falciparum malaria; Rabies
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 10 Sep 2008 Actual patient number (540) added as reported by ClinicalTrials.gov.
    • 10 Sep 2008 Rabies vaccine identified as an additional treatment arm as reported by ClinicalTrials.gov.
    • 25 Jul 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top